IP Library Granted Patent US 9,421,177
Granted Patent B2
US 9,421,177 · App. 13/390,207 · Granted Aug 23, 2016

Imidamide sphingosine kinase inhibitors

Inventors: Kevin R. Lynch (Charlottesville, VA); Timothy L. Macdonald (Charlottesville, VA); Thomas P. Mathews (Nashville, TN); Andrew Kennedy (Charlottesville, VA); Yugesh Kharel (Charlottesville, VA)
Assignee: University of Virginia Patent Foundation
A61K31/155C07C257/16C07D207/09C07C2101/02C07C2101/08C07C2101/14C07C2103/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,421,177
App. No.
13/390,207
Granted
Aug 23, 2016
Kind
B2
Abstract

Imidamide (amidine) analogs that can inhibit the activity of sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) are provided. The compounds can prevent angiogenesis in tumors.

Claims (20)

1. A compound of formula IA:

wherein

R 1 is hydrogen or OH;

Y is C═O (carbonyl);

Z is

A. (C 12 -C 20 )alkylaryl, wherein Z is optionally substituted with a (C 6 -C 10 )alkoxycycloalkyl, (C 6 -C 10 )alkoxyphenyl, phenyl, or a (C 3 -C 7 )cycloalkyl;

B. (C 5 -C 12 )alkyl-4-phenyl substituted with (C 5 -C 10 )cycloalkyl—O; or

C. a substituent selected from the group consisting of

or a pharmaceutically acceptable salt or ester thereof.

2. The compound of claim 1 , wherein R 1 is hydrogen.

3. The compound of claim 1 , wherein R 1 is —OH.

4. The compound of claim 1 , wherein Z is

5. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , having the formula:

7. A compound of claim 1 , which inhibits the activity of SphK1 and SphK2.

8. A compound of claim 1 , which selectively inhibits SphK1.

9. A compound of claim 1 , which selectively inhibits SphK2.

10. A pharmaceutical composition comprising a compound having the formula of claim 1 or 5 , and a pharmaceutically acceptable carrier.

11. The composition of claim 10 , wherein the composition is in the form of a kit.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 6, 2016
From: UNIVERSITY OF VIRGINIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039917/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2012
From: LYNCH, KEVIN R.; MACDONALD, TIMOTHY L.; MATHEWS, THOMAS P.; KENNEDY, ANDREW; KHAREL, YUGESH
To: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Reel/Frame 028119/0001 →
Continuity (2)
Provisional Application 61233963 · Aug 14, 2009
Related Publication 20120214858A1 · Aug 23, 2012